Loading company…
Pep2Tango Therapeutics develops peptide drugs for obesity and related metabolic disorders.
Pep2Tango Therapeutics develops peptide medicines for metabolic, endocrine, CNS and cardiovascular disorders. Its obesity research includes multi-receptor agonist peptides targeting GLP-1, GIP, amylin and calcitonin. Founded in 2021, the company is based in Maryland and led by CEO Cristina Rondinone. In November 2024, it received an undisclosed amount of venture funding from Versant Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in